THDB

Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning capsules; pediatric paracetamol and artificial cow-bezoar and chlorphenamine maleate granules; zhennaoning capsules; compound methionine and choline bitartrate tablets; and compound kushen changyankang tablets. It also provides insulin pens and pen needles; and the Chronic Disease Management Platform, which is a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, the company offers oral anti-diabetic hypoglycemic drugs, such as sitagliptin phosphate, sitagliptin phosphate/metformin hydrochloride, repaglinide, and engagliflozin tablets.